F&P Healthcare to take $5-10M hit in patent stoush
Fisher & Paykel Healthcare is going toe to toe with rival ResMed.
AdvertisementAdvertise with NZME.
Latest fromFisher and Paykel Healthcare
Market has priced FPH at perfection, say analysts
Shares in Fisher & Paykel Healthcare fell slightly, despite another record result.
F&P Healthcare posts record result, nears $1 billion revenue
Fisher & Paykel Healthcare has posted another record result
F&P Healthcare boosts profits
Annual profit is likely to be between $185 million and $190 million.
F&P Healthcare wins patent case against ResMed
F&P Healthcare wins patent case against ResMed in UK Court.
Soaring Kiwi tech sector tops $10b of revenue: report
NZ tech companies have recorded over $10 billion in revenue for the first time.
F&P Healthcare may appeal ruling on Resmed
The ruling in Germany says ResMed did not infringe its patents.
Mercury leads sharemarket higher
NZ Refining stock falls amid pipeline repiar, while Synlait retreats from high.
F&P Healthcare lowers guidance on strong NZD
Fisher & Paykel Healthcare lowered full year earnings guidance due to the strong NZ dollar
F&P Healthcare boss sells shares to buy house
Lewis Gradon sold almost half of his shares, raising about $3.1 million to buy a house.
Embracing governance issues
COMMENT: Companies with higher ESG ratings are, on average, outperforming their peers.
Macquarie lifts F&P price target by 7.3pc
Macquarie Group lifted its 12-month target price on F&P Healthcare by 7.3 per cent
F&P Healthcare positive about future
Profit rose to a record $169m in the 12 months ended March 31, from $143m a year earlier.
Do young companies need a board to grow?
COMMENT: Problems can rise in scaling start-ups into a larger sustainable company.
F&P's new boss, just like the old boss
Business as usual is delivering results for healthcare company's chief executive.
SFO charges former F&P Healthcare manager
Former F&P healthcare manager pleads guilty to charges.
Improving board effectiveness
COMMENT: Boardroom conversation is an art form for some and a learned skill for others.
F&P's cunning plan to avoid Trump's tax
US President plans a 20% tax on goods from Mexico, where F&P Healthcare manufactures medical equipment, but the Kiwi company has a work-around.
Are directors performing at their best?
COMMENT: Governance cannot be that bad, given the growing interest in directorships from many individuals.
Former F&P Healthcare boss wins top award
Michael Daniell has won the New Zealand Shareholders Association's 2016 Beacon Award
F&P Healthcare posts 26pc gain
Fisher & Paykel Healthcare, the medical device maker, increased first-half profit 26 per cent and widened its margins.
F&P files patent infringement against ResMed
F&P Healthcare has filed a patent infringement lawsuit against ResMed, claiming it used its tech in its breathing masks and air flow products.
Portfolio manager bought shares to push up price, court told
Details of the case against Milford Asset Management's Mark Warminger were revealed in court today.
F&P Healthcare profit jumps 27pc
Fisher & Paykel Healthcare beat its forecast for annual profit, boosting revenue and margins.
Henri Eliot: Do you want to know the skill set of company directors?
Henri Eliot talks publishing a skills matrix that provides shareholders with the information needed to evaluate a board's skill set mix.
Diligent, F&P tipped as stars of next year
Brokers are picking Fisher & Paykel Healthcare, Diligent and Infratil to be among the NZX's top-performing stocks in 2016.
Henri Eliot: What should worry directors in 2016?
Henri Eliot talks to professional directors Mark Verbiest, Tony Carter, Doug McKay and Rob Campbell about their focal points in 2016.
F&P Healthcare record profit rise
Fisher & Paykel Healthcare's first-half profit rose to a record $62 million.
F&P Finance sale battle hotting up
Efforts to sell Fisher & Paykel Finance are gathering momentum, but mixed messages are emerging over when the deal might be clinched.
F&P Healthcare boss steps down
The departure of Fisher & Paykel Healthcare chief executive Mike Daniell might unsettle some investors but is unlikely to derail the company, say market players.